VG Health

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Meiwu Tech

Amesite

InMed Pharmaceuticals

Generation Income Properties

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Co-Diagnostics

MetaVia

Phoenix Asia

BAYVIEW ACQUISITION CORPORATION COM USD0.0001 (S/R) 17/11/2028

Gen Digital - Rights

Pinned News

置顶新闻

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

The latest batch of 13F filings has been released: In Q1, Berkshire Hathaway increased its stake in Google Class A shares by over 200%, propelling it to the position of its seventh-largest holding. The firm completely exited positions held for nearly seven years—including Amazon, as well as Visa, Mastercard, and UnitedHealth—while simultaneously making a return to the airline sector after a six-year hiatus, investing $2.65 billion to establish a new position in Delta Air Lines. Bridgewater Associates, meanwhile, initiated new positions in TSMC and the Gold ETF (GLD) for the first time; it also increased its holdings in Amazon (elevating it to its top holding), Nvidia, Broadcom, and Micron. Conversely, the firm liquidated its stakes in Salesforce and ServiceNow, and trimmed its positions in Mastercard, Adobe, and others. Institutional capital is currently converging on AI computing power and safe-haven assets. How many of the stocks in your portfolio have caught the eye of these investment giants?

Big funds' 13Fs are out: betting on AI compute and safe havens

GILD

ARKG

LABU

SBIO

IBBQ

ProShare Advisors LLC increased its stake in Gilead Sciences, Inc. by 39.1% in Q4, acquiring 623,752 shares, bringing its total to 2,217,290 shares valued at $272.15 million. Other institutional investors also adjusted their holdings. Gilead's stock opened at $129.67, with a market cap of $160.99 billion. The company reported $2.03 EPS, exceeding estimates, and announced a quarterly dividend of $0.82 per share.

Market Beat

Gilead Sciences

Gilead Sciences, Inc.

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares Global Healthcare

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

ABVX

D.E. Shaw disclosed a 1.24% net short position in Abivax shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

PUBT

Abivax SA

D.E. Shaw discloses net short position in Abivax shares

WELL

10:46 AM EST - WELL Health Technologies Corp. : Announced that the Notice of Intention to Make a Normal Course Issuer Bid it filed with the Toronto Stock Exchange has been approved by the TSX and has subsequently entered into an automatic share purchase plan with a broker in order to facilitate repurchases of the Company's common shares. The NCIB is a renewal of its NCIB that is set to expire on May 19. WELL Health Technologies Corp. shares T.WELL are trading down $0.015 at $3.94.

Baystreet

Welltower Op

SPDR S&P Health

iShares US Healthcare Providers

Stocks in Play: WELL Health Technologies Corp.

LLYX

President Trump purchased $680,000 in Eli Lilly (LLY) stock around the FDA's approval of a new weight-loss pill. The timing of these trades coincides with favorable government decisions benefiting Lilly, including a Medicare reimbursement pilot program for GLP-1 drugs. Trump's stock trades, disclosed in ethics forms, include various investments across sectors, but Lilly's trades stand out due to their potential impact on the company's revenue growth, projected to exceed $80 billion in 2026.

Tip Ranks

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Microsoft

NVIDIA

Boeing

Target

Chipotle Mexican Grill

West Pharmaceutical

Citigroup

Toronto Dominion Bank

NVIDIA Corporation

Boeing Company

CITIGROUP INC 6.250 NON CUM SER II PFD WI

President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill

INCY

LABD

Incyte Stock: Analyst Estimates & Ratings

Barchart Option

Incyte

Direxion S&P Biotech Bear 3X

Incyte Stock: Analyst Estimates & Ratings

Daiwa Securities Group has lowered its target price for Gilead Sciences (NASDAQ:GILD) from $161.00 to $150.00 while maintaining an 'outperform' rating. This new target suggests a potential upside of 14.66%. Other analysts have varied opinions, with Barclays setting a $155.00 target and Wells Fargo raising theirs to $165.00. Gilead's stock is currently trading at $130.82, with a market cap of $162.42 billion and a P/E ratio of 17.85.

Daiwa Securities Group Inc.

Barclays

Wells Fargo

Mizuho Financial

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Mizuho Financial Group, Inc.

Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

STRO

Duality Biotherapeutics has announced a share buyback plan of up to USD 40 million, funded from internal resources, with shares to be held as treasury stock. Chairman and CEO Zhu Zhongyuan will also purchase up to USD 5 million in shares using personal funds. The announcement was made on May 19, 2026.

Sutro Biopharma

DUALITYBIO-B

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

Duality Biotherapeutics plans share buyback of up to US$40 million

JPMorgan Chase & Co. has lowered its price target for HCA Healthcare from $535.00 to $490.00, maintaining a 'neutral' rating. The stock currently has a consensus rating of 'Moderate Buy' with an average target price of $515.77. HCA's stock traded down to $405.77, with a market cap of $90.02 billion. Analysts forecast an EPS of 30.07 for the current fiscal year.

HCA Healthcare

JPMorgan Chase

Goldman Sachs

KeyCorp

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

GS Hldg R

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

HCA Healthcare (NYSE:HCA) Price Target Cut to $490.00 by Analysts at JPMorgan Chase & Co.

ABBV

AbbVie and CVS Health appear expensive with trailing P/E multiples over 40, but non-recurring expenses inflate these figures. AbbVie’s forward P/E is 15, while CVS Health’s is 13, indicating they may be undervalued. AbbVie faced a significant drop in net income due to a $2.7 billion charge, while CVS reported a $4 billion loss from goodwill impairment. Both companies show potential for better performance, making them attractive investment options despite their current valuations.

nasdaq

CVS Health

Abbvie

Intel

S&P 500

2 Stocks That Are Much Cheaper Than They Look

DoctorDerm has announced a comprehensive rebrand and the expansion of its telehealth dermatology platform, introducing new prescription treatments. The rebrand emphasizes simplicity and personalized care, moving away from one-size-fits-all solutions. New offerings include the Copper Peptide Skin Complex for skin quality and the Lash Growth Serum for enhancing lash appearance. Both treatments are available nationwide after evaluation by licensed providers, reflecting DoctorDerm's commitment to accessible, clinically guided skincare.

MorningStar

DoctorDerm Unveils Rebrand and Expands Platform with New Prescription Skin and Lash Treatments

513060

On May 19, 2026, the leading sector was the Energy Select Sector SPDR ETF (XLE) with a price change of +0.22%. The Health Care Select Sector SPDR ETF (XLV) also gained slightly. Conversely, the Technology Select Sector SPDR ETF (XLK) led the losses with a decline of -1.95%, followed by the Industrial (XLI) and Consumer Discretionary (XLY) sectors. This data helps traders analyze market trends for better investment decisions.

VG Health(VHT.US)

ProShare Advisors LLC Buys 623,752 Shares of Gilead Sciences, Inc. $GILD

D.E. Shaw discloses net short position in Abivax shares

Stocks in Play: WELL Health Technologies Corp.

President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill

Incyte Stock: Analyst Estimates & Ratings

Daiwa Securities Group Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Duality Biotherapeutics plans share buyback of up to US$40 million

HCA Healthcare (NYSE:HCA) Price Target Cut to $490.00 by Analysts at JPMorgan Chase & Co.

2 Stocks That Are Much Cheaper Than They Look

DoctorDerm Unveils Rebrand and Expands Platform with New Prescription Skin and Lash Treatments

Leading And Lagging Sectors For May 19, 2026